NewsRoom Articles - Page 1315 of 1352

MondayDec 05, 2016 5:01 pm

Neuralstem, Inc. (CUR) Gets Aegis Update

Neuralstem, Inc. (NASDAQ: CUR) is a biotechnology company whose patented technology allows for the production, on a commercial level, of a number of types of central nervous stem cells. These are in the development stage for the treatment of conditions and diseases of the central nervous system. The company recently announced the start of enrollment of patients for its phase II trial of NSI-189, a drug developed after Neuralstem did research into neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of neurons. On November 7 of this year, Aegis…

MondayDec 05, 2016 12:27 pm

Singlepoint (SING) Subsidiary Looks to Help Cannabis Merchants Build Trust, Increase Customer Loyalty

A leading provider of mobile technology and mobile payment solutions serving various markets and industries, Singlepoint, Inc. (OTC: SING) has its eyes set on the fast-growing cannabis industry, aiming to help legal marijuana businesses build trust and increase customer loyalty via subsidiary SingleSeed and its highly reliable payment processing and marketing tools. With eight more states voting to legalize either medical or recreational marijuana use last month, the marijuana industry is set to exceed $7 billion this year and to reach roughly $20 billion by 2020. However, legal businesses operating in the sector still find it hard to obtain support…

MondayDec 05, 2016 10:56 am

Net Element, Inc. (NETE) Subsidiary PayOnline Enters Azerbaijan through Agreements with AGBank, Flight.az

Before the opening bell, Net Element, Inc. (NASDAQ: NETE), through subsidiary PayOnline, announced a new partnership with Flight.az, a subsidiary of Delta Group, Ltd that’s recognized as a leading online travel agency (OTA) in Azerbaijan. Under the terms of this contract, PayOnline integrated secure online, mobile payments acceptance functionality, as well as its proprietary ‘Avia2Split’ technology, into the OTA’s existing booking platform, giving Flight.az the tools to better serve its target market of roughly 10 million people living in Southwestern Asia. PayOnline’s newly-announced entry into the Azerbaijani market comes on the heels of a new agreement with AGBank, one of…

MondayDec 05, 2016 9:16 am

European Patent Dispute Spurs Buying Opportunity with Higher Price Target for Alder Biopharmaceuticals (ALDR)

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), according to an analysis report (http://nnw.fm/8j0TO) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a ‘Buy’ rating for the company and proposed a higher stock price target of $41, compared to the $25.28 stock price at the time the report was issued. The report acknowledges that the ruling by the European Patent Office’s Opposition Division is unfavorable to product candidate ALD403 and…

FridayDec 02, 2016 3:44 pm

Singlepoint, Inc. (SING) CEO Discusses Influx of Calls from Cannabis Dispensaries on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, offered prospective investors an update on the progress of the company’s SingleSeed subsidiary, which it awakened from a quiet period in early November in an effort…

FridayDec 02, 2016 1:09 pm

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®). Most recently, the company announced positive top-line phase III results for M923,…

FridayDec 02, 2016 12:34 pm

SQI Diagnostics, Inc. (SQIDF) Changing How Diagnostics Testing Works

Diagnostic labs and drug developers are in a constant search for cheaper, better, faster test results, and SQI Diagnostics (OTCQX: SQIDF) is focused on meeting this demand. The company reduces the timeline for urgently-needed test results and the amount of labor needed, all without forfeiting quality. SQI Diagnostics is a life sciences and diagnostics company that supports better health care through the development and marketing of technologies and products that propel faster and more accurate advanced multiplexing diagnostics. From SQI’s base in Toronto, a team of expert scientists develops custom research and diagnostic assays that are multiplexed to consolidate and…

FridayDec 02, 2016 12:05 pm

Fortress Biotech, Inc. (FBIO) set to Profit from Profuse Product Portfolio

Fortress Biotech, Inc. (NASDAQ: FBIO) is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might tip his hat to the way the company has sought to mitigate developmental risks. Fortress’ diverse product pipeline also gives it multiple shots at hitting its financial goals, increased by the symbiotic relationship between development areas. The research platforms are structured so that success in one area is likely to add impetus to another. Fortress is parent to a group…

FridayDec 02, 2016 11:07 am

Agora Holdings, Inc. (AGHI) Aims to Streamline Personal Branding with FRAME

Before the opening bell, Agora Holdings, Inc. (OTC: AGHI) issued an update on its FRAME social media management technology, providing some additional insight into how the platform can be used to streamline personal branding efforts for both individuals and businesses. The news release highlights the importance of establishing and maintaining a presence on social media in order to accomplish a variety of goals. Whether created to stay connected, meet new people, get the word out about a new business or run for public office, maintaining an effective online presence is made easier with Agora’s recently launched FRAME technology. “The boundary…

FridayDec 02, 2016 9:11 am

Akebia Therapeutics (AKBA) ‘Buy’ Rating Reiterated with Higher Stock Price Target of $18

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its ‘Buy’ rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report (http://nnw.fm/F4ezY) released on November 15. The rating and suggested stock price were based on discounted cash flow analysis and the estimated 2016-2022 EBITDA, with a discount rate of eight percent, the report said. The analysis also assumed a 60 percent probability of clinical success for Akebia’s lead product candidate Vadadustat, currently in development as…

Financial news and publishing for public and private companies

Contact us: 512.354.7000